National Center for Advancing Translational Sciences

NCATS
CFDA 93.350 Active Grant Cooperative Agreement

Open Opportunities (14)

Live Grants.gov opportunities funded under this program — you can apply now.

See all grants from National Institutes of Health →

Program Funding

Annual program obligations reported to SAM.gov.

Latest annual funding
$626.2M FY2025
$595.6M
FY24
$626.2M
FY25

Who has received this funding

Organizations awarded under CFDA 93.350 (USAspending.gov).

Program Objective

NCATS' mission is to turn research observations into health solutions through translational science. We work to develop or enhance the development, testing, and implementation of diagnostics and therapeutics for a wide range of diseases and conditions. Key approaches include understanding what’s similar across diseases to spur multiple treatments at a time, developing models that better predict a person’s reaction to treatment, enhancing clinical trials so results more accurately reflect the patient population, and leveraging real-world data and data science approaches to address public health needs. Facilitating these approaches are our robust partnerships with other government agencies, including other NIH institutes, centers, and offices; industry; academia; nonprofit organizations; and patients, patient advocates, and other communities.
NCATS' vision is to bring more treatments for all people more quickly.

Eligibility

Eligible Applicants

  • U.S. Federal Government
  • U.S. State Government
  • U.S. Territory Government
  • Department/Agency of U.S. State
  • Department/Agency of U.S. Territorial Gov
  • Interstate Organization
  • Federally Recognized Tribal Government
  • Tribal Government (other)
  • Tribally Designated Housing Authority
  • Municipality/Township Government
  • County Government
  • School District Government
  • School District
  • Local Government Consortium
  • Public Housing Authority
  • Other Special District Government
  • Local
  • State
  • Territorial
  • Tribal
  • Foreign Government
  • Foreign Nonprofit Organization
  • Foreign Not-for-Profit Organization
  • Foreign For-Profit Organization
  • International Organization
  • Nonprofit Organization
  • Not-for-Profit Organization
  • For-Profit Organization

See above.

How to Apply

Award Procedure

The initial review of applications from eligible institutions is conducted by committees comprised of authorities in various fields of biomedical research and science education, as appropriate. Each application is given a peer evaluation for merit. Recommendations for award are forwarded to the NCATS Advisory Council for the second level of review and recommendation for award.

Decision Timeline

  • Approval: > 180 Days
  • Renewal interval: > 180 Days
  • Appeal: From 15 to 30 days
Program details & compliance

Description

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) was established to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients.

Mission Categories

Primary: Research and Development

Other categories:
Capacity Building/CybersecurityMedical EducationGeneral Health and Medical

Use of Funds

Allowed Uses

NCATS is all about getting more treatments to all patients more quickly. There are more than 10,000 known rare diseases and only a few hundred have safe, effective treatments. A novel drug, device or intervention can take 14 years and $2 billion to develop, with a failure rate exceeding 95%. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. The Clinical and Translational Science Award (CTSA) Program supports a national, collaborative consortium focused on bringing more treatments to all people more quickly through advancing clinical and translational science. The Trial Innovation Network, inclusive of Trial Innovation Centers and a Recruitment Innovation Center, are intended to serve as a national model for innovation in clinical trial management and operations, participant recruitment, and will facilitate the implementation of multi-site clinical studies by the CTSA network. The CTSA Collaborative and Innovation Acceleration Awards supports synergistic activities that accelerate the translational research process through collaboration and innovation. NCATS supports a network of research consortia, each targeted to several related rare diseases. NCATS also supports an extensive resource of information for the public on rare diseases. NCATS supports expansion of the target landscape for therapeutic development by supporting pilot studies on druggable proteins that have largely been neglected by the research community, but are associated with rare diseases. It also supports strategies that will enable targeting biologic entities that cannot be modulated with traditional drug development of biologic strategies. In cases where a potential therapeutic has been identified for a rare disease, and a model system for testing the treatment has already been established, NCATS will support proof of concept studies to advance development of the candidate treatment. NCATS also supports early-stage development projects for generalizable translational science technologies. Through Translator, NCATS will integrate existing biomedical data to help reveal new relationships within those data and also identify novel opportunities for research. Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs utilize the grant and cooperative agreement mechanisms to help eligible US based small businesses develop new translational technologies that can eventually be commercialized to provide health solutions. SBIR and STTR foster participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons. The Tissue Chip program funds bioengineered devices to improve the process of predicting whether drugs will be safe or toxic in humans. The bioprinting program will generate high throughput screenable assay models of human tissues for drug discovery. Quantum Biomedical Innovations and Technologies (Qu-BIT) Program aims to generate innovative quantum-enabled sensing technologies and quantum computing approaches to provide novel capabilities in early disease detection, improving diagnostic approaches, and therapeutic strategies. The NCATS ASPIRE Program develops technology platform for improving drug discovery and pre-clinical testing of new and safer treatments.

Required Documentation

The required credentials of the applicant are described in the relevant Funding Opportunity Announcement.

Reporting & Compliance

Records Retention
3 years

Applicable 2 CFR 200 Subparts

  • Subpart B — General Provisions
  • Subpart C — Pre-Federal Award Requirements
  • Subpart D — Post-Federal Award Requirements
  • Subpart E — Cost Principles
  • Subpart F — Audit Requirements

Contacts

NCATSExtramuralInfo
301-594-8966
9609 Medical Center Drive, Rockville, MD 20850
Data from SAM.gov Federal Assistance Listings. Source published: 2026-01-28. Spec v2.0. Last synced: 2026-05-29 05:40:50.

The free database of U.S. federal grants for nonprofits and grant writers — updated daily from official sources, Grants.gov, SAM.gov and other official resources.

✓ 100% free   ✓ No account required   ✓ Direct links to official applications

More categories
More applicant types
More states
More funders
Explore
Company
Help